Journal:
:hepatitis monthly
0
jacqueline k flynn centre for biomedicine, burnet institute, melbourne, australia; department of infectious diseases, monash university, melbourne, australia; centre for biomedicine, burnet institute, 3001 victoria, g.p.o. box: 2284, melbourne, australia. tel: +61-392822109, fax: +61-392822100
rachel sacks-davis centre for population health, burnet institute, melbourne, australia; department of epidemiology and preventive medicine, monash university, melbourne, australia
peter higgs centre for population health, burnet institute, melbourne, australia; department of epidemiology and preventive medicine, monash university, melbourne, australia; national drug research institute, faculty of health sciences, curtin university, melbourne, australia
campbell aitken centre for population health, burnet institute, melbourne, australia; department of epidemiology and preventive medicine, monash university, melbourne, australia
sarah moneer department of microbiology and immunology, university of melbourne, parkville, australia
vijay suppiah storr liver unit, westmead millennium institute, university of sydney, sydney, australia; school of pharmacy, university of south australia, adelaide, australia
conclusions this study demonstrated the detection of hcv-specific ifn-γ responses in hcv antibody and rna negative individuals, with a tendency for hcv-specific ifn-γ responses to be associated with hcv exposure. the potential role of hcv-specific ifn-γ responses in those who remained hcv rna negative is of value for the development of novel hcv therapeutics. objectives in a cohort of hcv antib...